Method for classifying fine dust exposure and predicting pregnancy-related complications caused by fine dust exposure

By quantifying arabinose, ribose, and xylose in biological samples, the method effectively classifies fine dust exposure and predicts pregnancy complications, addressing the limitations of existing methods in accurately assessing indoor fine dust exposure and its impacts on pregnancy outcomes.

WO2024248487A1PCT designated stage expired Publication Date: 2024-12-05EWHA UNIV IND COLLABORATION FOUND +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007352
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods lack effective and accurate means to classify fine dust exposure and predict pregnancy-related complications, particularly indoors, where most individuals spend 80-90% of their time, due to the complexity of fine dust components and the difficulty in sampling biomarkers like DNA methylation or telomere length in cord blood.

Method used

A method involving the quantification of specific metabolites such as arabinose, ribose, and xylose in biological samples from pregnant women to classify exposure to fine dust and predict associated pregnancy complications, using techniques like gas or liquid chromatography, HPLC, and mass spectrometry to differentiate exposed individuals and predict risks.

Benefits of technology

This approach allows for accurate classification and prediction of fine dust exposure and associated pregnancy complications like low birth weight, premature birth, and gestational diabetes, enabling early intervention and prevention measures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007352_05122024_PF_FP_ABST
    Figure KR2024007352_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a method for classifying fine dust exposure and predicting pregnancy-related complications caused by fine dust exposure. The method of the present invention is used for the classification of fine dust exposure and the prediction of pregnancy-related complications caused by fine dust exposure, which are based on biochemical markers, and thus is advantageous in that an appropriate prevention or intervention plan for chronic diseases and children's respiratory diseases caused by fine dust exposure can be constructed or, especially, pregnancy-related complications such as a low-birth-weight infant, premature birth and gestational diabetes, which are difficult to identify until birth or onset, can be quickly predicted with high accuracy.
Need to check novelty before this filing date? Find Prior Art

Description

Classification of fine dust exposure and prediction of pregnancy-related complications due to fine dust exposure

[0001] The present invention relates to a technology for classifying fine dust exposure and a method for predicting pregnancy-related complications due to fine dust exposure, and more specifically, to a technology for providing information for classifying pregnant women exposed to fine dust or predicting pregnancy-related complications due to fine dust, a composition and kit for classifying fine dust exposure, and a composition and kit for predicting the onset of pregnancy-related complications due to fine dust exposure.

[0002] Fine dust is a complex, suspended particle in the atmosphere. It is mostly derived from vehicle exhaust fumes and dust generated during road traffic, and the size and chemical composition of the particles determine their health impact. Exposure to fine dust is associated with respiratory and cardiovascular diseases and has been reported to increase mortality. In particular, fine dust particles smaller than 10 micrometers in size pose a significant health risk because they can enter the lungs and bloodstream.

[0003] In a study of elderly people living in Illinois, USA, the concentration of fine dust was 10 ㎍ / m 3 It was found that people who had myocardial infarction had a 2.5-fold increase in mortality rate, and people with diabetes had a 2.0-fold increase in mortality rate. In a Korean study, it was found that people with heart failure had a 2.5-fold increase in mortality risk.

[0004] Furthermore, mortality rates from respiratory diseases increased in children exposed to fine dust, and exposure to these pollutants during the developing lungs can have lasting effects on lung function in adulthood. A follow-up study of schoolchildren in California found that children exposed to these pollutants over a long period were 4.9 times more likely to have impaired lung function as adults. Furthermore, this decline in lung function is known to increase the risk of cardiovascular disease and diabetes.

[0005] In addition, fine dust 2.5 (PM 2.5), one of the air pollutants 2.5 , particles with an aerodynamic diameter of ≤2.5 μm) have been reported to be associated with various adverse pregnancy outcomes. In particular, PM 2.5 Although an association has been reported between low birth weight, low birth weight for gestational age, and premature birth, most studies have assessed particulate matter exposure based on outdoor air quality measurements.

[0006] Low birth weight (LBW, birth weight <2,500 g, regardless of gestational age), small for gestational age (SGA, birth weight below the 10th percentile for gestational age), and preterm birth (PTB, delivery at <37 weeks of gestation) are pregnancy complications that directly affect neonatal outcome. The incidence of LBW varies across countries but ranges from 6% to 25%, and LBW is known to be associated with short- and long-term complications. In addition, the prevalence of LBW is known to be approximately twice that of low birth weight.

[0007] In the past, most studies were conducted based on outdoor air quality measurements taken at outdoor measuring stations. However, with 80-90% of individuals living indoors, the importance of indoor air quality is increasingly being emphasized, and the importance of indoor fine dust concentration measurement and indoor air quality management is increasing. PM ​​is linked to various pregnancy complications, including fetal growth. 2.5 The pathogenesis of ovarian cancer remains poorly understood, and research on biomarkers developed to monitor exposure to ovarian cancer is also lacking. Attempts have been made to explain fetal growth based on DNA methylation or telomere length in cord blood, but cord blood is difficult to sample during pregnancy, making it unsuitable for biomonitoring.

[0008] As such, exposure to fine dust is closely related to chronic diseases, respiratory diseases in children, and pregnancy-related complications. Therefore, it is necessary to develop a method that can accurately predict pregnancy-related complications caused by fine dust exposure without affecting the fetus during pregnancy by identifying pregnant women exposed to fine dust in advance and devising appropriate preventive or intervention measures.

[0009] The purpose of the present invention is to provide a method for providing information for distinguishing pregnant women exposed to fine dust, comprising the step of (a) quantifying the level of at least one metabolite selected from the group consisting of arabinose, ribose, and xylose from a sample of a subject suspected of being exposed to fine dust.

[0010] Another object of the present invention is to provide a composition for distinguishing exposure to fine dust, or a composition for predicting the onset of pregnancy-related complications due to exposure to fine dust, comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

[0011] Another object of the present invention is to provide a kit for distinguishing exposure to fine dust or a kit for predicting the onset of pregnancy-related complications, the kit comprising a composition comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose and xylose.

[0012] To avoid confusion due to overlapping content, the description of redundant content will be omitted below. In other words, the content of the invention is not limited to the content described below, and the content of the invention should be interpreted based on the overall content of the invention.

[0013] The present invention provides a method for providing information for distinguishing between pregnant women exposed to fine dust or predicting pregnancy-related complications caused by fine dust, a composition and kit for distinguishing between exposure to fine dust, and a composition and kit for predicting the onset of pregnancy-related complications caused by exposure to fine dust.

[0014] As one aspect for achieving the above purpose, a method for providing information for distinguishing pregnant women exposed to fine dust is provided, comprising the step of (a) quantifying the level of at least one metabolite selected from the group consisting of arabinose, ribose, and xylose from a sample of a subject suspected of being exposed to fine dust.

[0015] As a specific aspect thereof, a method for providing information for distinguishing a pregnant woman exposed to fine dust is provided, comprising: (a) a step of quantifying the level of at least one metabolite selected from the group consisting of arabinose, ribose, and xylose from a sample of a subject suspected of being exposed to fine dust; and (b) a step of determining that the pregnant woman is exposed to fine dust when the level of the metabolite is increased compared to at least one metabolite selected from the group consisting of arabinose, ribose, and xylose of a corresponding normal control group as a result of quantifying the level of the metabolite.

[0016] More specifically, (b) the step of predicting that there is a risk of developing pregnancy-related complications due to exposure to fine dust when the level of the metabolite is increased as a result of quantifying the level of the metabolite compared to at least one selected from the group consisting of arabinose, ribose, and xylose of the corresponding normal control group; may further include;

[0017] That is, it is possible to provide a priority classification of pregnant women due to exposure to fine dust and additionally provide a prediction of the risk of developing pregnancy-related complications due to exposure to fine dust.

[0018] The above “fine dust” may preferably be ultrafine dust or extremely fine dust (PM 2.5) having a particle size of 2.5㎛ or less.

[0019] The above "comparing the level of metabolites (arabinose, ribose, xylose) with that of the corresponding normal control" means comparing the metabolic level of a specific metabolite of the subject being predicted.

[0020] The above “metabolite level” may be a quantitative measurement of the quantity, level, distribution, distribution ratio or concentration of a metabolite (arabinose, ribose, xylose) in a biological sample.

[0021] The above “level increase” may be an increase in the quantity, level, distribution, distribution ratio or concentration of a metabolite (arabinose, ribose, xylose) within a biological sample.

[0022] Preferably, the subject may be a mammal. In some embodiments, the subject may be a human.

[0023] The term "sample of a subject" used in the present invention means any sample obtained from an individual from which the metabolite of the present invention can be detected.

[0024] According to a preferred embodiment of the present invention, the sample of the subject is a biological sample separated from the subject, more preferably any one selected from the group consisting of blood, saliva, feces, vaginal fluid and urine separated from the subject, and can be prepared by processing by a method commonly used in the technical field of the present invention.

[0025] The above normal control group may refer to a biological sample recovered from a healthy person (especially, a pregnant woman) or mammal not exposed to fine dust. The above "step of quantifying metabolites" may be performed by at least one selected from the group consisting of a gas or liquid chromatography device, a high-performance liquid chromatography (HPLC) device, a thin layer chromatography (TLC), an electrochemical analysis device, a refractive index spectroscopy device, a fluorescence analysis device, a radiochemical analysis device, a light scattering analysis device, a nuclear magnetic resonance spectroscopy, an ultraviolet spectroscopy, an infrared spectroscopy, an enzyme-linked immunosorbent assay (ELISA), and a mass spectrometer. Since these methods are well known, their description is omitted.

[0026] According to one embodiment of the present invention, the metabolite according to the present invention showed a significant increase in the level in a group with high exposure to fine dust, and it was confirmed that the metabolite distinguished the fine dust exposure group with high accuracy. Therefore, by distinguishing pregnant women exposed to fine dust using the method according to one embodiment of the present invention, the risk of fine dust exposure can be identified in advance, allowing for the development of appropriate preventive or intervention measures.

[0027] In addition, the present invention provides a method for providing information for predicting the onset of pregnancy-related complications due to fine dust exposure, comprising, as a specific embodiment, (a) a step of quantifying the level of at least one metabolite selected from the group consisting of arabinose, ribose, and xylose from a sample of a subject suspected of being exposed to fine dust; and (b) a step of predicting that there is a risk of developing pregnancy-related complications due to fine dust exposure when the level of the metabolite is increased compared to at least one metabolite selected from the group consisting of arabinose, ribose, and xylose of a corresponding normal control group as a result of quantifying the level of the metabolite.

[0028] Preferably, the subject may be a mammal. In some embodiments, the subject may be a human, more specifically, a pregnant woman suspected of being exposed to fine dust.

[0029] According to a preferred embodiment of the present invention, the sample of the subject is a biological sample isolated from a pregnant woman, and is not particularly limited thereto, but is preferably any one selected from blood, plasma, platelets, serum, ascites fluid, bone marrow fluid, lymph, saliva, tears, mucous membrane fluid, amniotic fluid, feces, vaginal fluid, and urine isolated from the subject, and can be prepared by processing using a method commonly used in the technical field of the present invention.

[0030] The above-mentioned normal control group may refer to a group with low estimated concentrations of particulate matter exposure during pregnancy. More specifically, it may be a randomly selected and quantified experimental group from a group with low estimated individual particulate matter exposure during pregnancy. Furthermore, in some cases, it may be a biological sample collected from a mother who delivered a baby weighing 2.5 kg or more at 37 weeks or more of gestation without any pregnancy-related complications, or a biological sample isolated from a pregnant woman without symptoms of pregnancy-related complications.

[0031] The term "pregnancy-related complications" may be any one selected from the group consisting of low birth weight, high risk of miscarriage and premature birth, intrauterine fetal death, congenital malformations, increased incidence of neonatal diseases, increased perinatal mortality in newborns, premature birth, and gestational diabetes.

[0032] The terms “low birth weight”, “low birth weight”, and “LBW” in the present invention have the same meaning and refer to the birth of a fetus with a birth weight of less than 2.5 kg regardless of gestational age. Among them, a case where the weight is less than 1.5 kg is called an extremely low birth weight infant. Many premature infants are small for gestational age due to intrauterine growth retardation, and all physical and metabolic functions such as body temperature regulation, spontaneous breathing, circulation, and digestion are delayed, and their resistance to infection is also weak. Therefore, predicting low birth weight infants is very important.

[0033] The terms "premature birth," "premature birth," "preterm birth," and "PTB" in the present invention have the same meaning and refer to the birth of a fetus before 37 weeks of gestation. Preferably, in the present invention, premature birth may be a premature birth before 34 weeks, which carries a particularly high risk.

[0034] The gestational age at which complications in premature babies are similar to those in term newborns is after 34 weeks of gestation. Since lung maturity occurs by 34 weeks, newborns born before 34 weeks are at a higher risk of developing fetal respiratory distress syndrome and therefore require medical assistance. Premature babies born before 34 weeks weighing less than 1.5 kg are placed in an incubator, and they are released from the incubator after 34 weeks of gestation, when they weigh more than 1.8 kg, and are able to regulate their body temperature. For these reasons, predicting premature birth before 34 weeks of gestation is crucial.

[0035] The terms “gestational diabetes”, “gestational diabetes”, “GDM”, etc. of the present invention have the same meaning and refer to a case where a person who did not originally have diabetes develops diabetes after the 20th week of pregnancy. When the insulin function of the pregnant woman decreases due to hormones secreted from the fetus, the pancreas normally increases insulin secretion to overcome this. When insulin secretion is insufficient, gestational diabetes develops.

[0036] Gestational diabetes requires special attention because it can affect both the fetus and the mother, and increases the risk of developing type 2 diabetes later in life. Furthermore, gestational diabetes increases the risk of giving birth to a fetal malformation, macrosomia, neonatal hypoglycemia, hypocalcemia, fetal neurological damage due to maternal ketoacidosis, and neonatal respiratory distress syndrome. Furthermore, after birth, the risk of childhood obesity and metabolic syndrome is twice as high as that of mothers with normal pregnancies, and the risk of developing gestational hypertension and premature birth is higher. Therefore, predicting gestational diabetes is very important.

[0037] According to one embodiment of the present invention, the metabolite according to the present invention showed a significant increase in level compared to other sugar metabolites, especially in the group highly exposed to fine dust, and it was confirmed that the metabolite was related to low birth weight, premature birth, and gestational diabetes due to fine dust exposure. Therefore, the method according to one embodiment of the present invention, that is, the metabolite according to the present invention, can be used as a predictive indicator for premature birth of less than 37 weeks, low birth weight of less than 2.5 kg, and gestational diabetes.

[0038] In the present invention, the term “prediction of the occurrence of pregnancy-related complications due to exposure to fine dust” refers to determining whether a pregnant woman exposed to fine dust is likely to have a low birth weight baby, premature birth, or gestational diabetes, has a relatively high probability of inducing the disease, or is likely to show signs of the disease.

[0039] The present invention can be used to delay or prevent the onset of pregnancy-related complications in pregnant women at high risk through special and appropriate management. Furthermore, the present invention can be clinically applied to treatment decisions by predicting the likelihood of developing the disease early and selecting the most appropriate treatment method.

[0040] Accordingly, the present invention can confirm the amount of metabolites (arabinose, ribose, xylose) of a normal control group and the amount of metabolites (arabinose, ribose, xylose) of a pregnant woman exposed to fine dust through the above detection method, and can predict pregnancy-related complications due to fine dust exposure by comparing the levels with the normal control group.

[0041] As described above, the present invention provides, as one embodiment for achieving the above object, a composition for distinguishing exposure to fine dust in pregnant women or a composition for predicting the onset of pregnancy-related complications due to exposure to fine dust, the composition comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

[0042] The above formulation may be capable of quantifying the quantity, level, distribution, distribution ratio or concentration of a metabolite in a biological sample.

[0043] The composition according to the present invention may be formed based on any one or more of the markers mentioned above, and may further comprise any of the markers mentioned above. That is, in the case of the markers, a combination of two or more may also be utilized.

[0044] According to one embodiment of the present invention, by extracting sugar metabolites from the urine of pregnant women and comparing them with those of normal people, three markers whose levels are specifically increased in the high-exposure group to fine dust were identified, and the purpose of using these markers is to predict the above-mentioned disease.

[0045] More specifically, the present invention confirmed that the levels of arabinose, ribose, and xylose increased in pregnant women who developed pregnancy complications (such as low birth weight, premature birth, and gestational diabetes) due to exposure to fine dust. Accordingly, using the above-described mechanism identified in the present invention, it is possible to classify pregnant women exposed to fine dust and predict pregnancy-related complications caused by fine dust exposure.

[0046] As described above, the present invention provides, as one embodiment for achieving the above object, a kit for distinguishing exposure to fine dust in pregnant women or a kit for predicting the onset of pregnancy-related complications, comprising a composition including a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

[0047] The above kit may be any one selected from the group consisting of a nuclear magnetic resonance spectroscopy device, a gas or liquid chromatography device, a high-performance liquid chromatography (HPLC) device, a thin layer chromatography (TLC), an electrochemical analysis device, a refractive index spectroscopy device, a fluorescence analysis device, a radiochemical analysis device, a light scattering analysis device, an ultraviolet spectroscopy device, an infrared spectroscopy device, an enzyme-linked immunosorbent assay (ELISA) device, and a mass spectrometry device.

[0048] Since the kit of the present invention comprises the above-described composition as a component, redundant descriptions are omitted to avoid excessive complexity of the present specification.

[0049] The classification of fine dust exposure and prediction of pregnancy-related complications due to fine dust exposure using the method of the present invention are based on biochemical markers, so that the risk due to fine dust exposure can be measured in advance and preventive or intervention measures can be devised, and in particular, there is an advantage in that it is possible to quickly and accurately predict pregnancy-related complications such as low birth weight, premature birth, and gestational diabetes, which are difficult to detect until birth or onset.

[0050] Figure 1 is PM 2.5 This is the result of confirming the association with pregnancy complications according to exposure concentration. (Preterm: premature birth, PIH: pregnancy-induced hypertension, Preeclampsia: preeclampsia, GDM: gestational diabetes, SGA: small for gestational age, LGA: fetal macrosomia, NICU: intrauterine growth retardation)

[0051] Figure 2 is PM 2.5 This is the result of a VIP scores plot, which lists metabolites that showed significant differences according to the degree of exposure in order of greatest influence from the top.

[0052] Figure 3 is PM 2.5 This is the result of a fold change plot targeting metabolites that showed significant differences according to the degree of exposure.

[0053] Figure 4 shows the ROC curve results for ribose, arabinose, and xylose.

[0054] Hereinafter, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the following examples.

[0055] Example 1. Investigating the Effects of Fine Dust on Mothers and Fetuses through Cohort Study

[0056] A. Materials and Methods

[0057] (1) Study design of Cohort I

[0058] The study included 1,880 pregnant women who delivered live babies at Ewha Womans University Mokdong Hospital between 2010 and 2015 (EUMC 2020-07-043). For the study, information on maternal age, body mass index (BMI), gestational age at birth (GAB), newborn sex, birth weight and length, APGAR (appearance, pulse, grimace, activity, and respiration) score, and residence at the time of delivery was collected. The Air Korea database is a database of air pollutants (SO2, PM) that the Ministry of Environment has compiled. 10 , including hourly cumulative air pollution monitoring data for components such as carbon monoxide, nitrogen dioxide, and ozone, particulate matter 2.5 (PM 2.5 ) It was used for exposure assessment. PM 2.5 Exposure levels were measured using the Community Multiscale Air Quality (CMAQ) modeling system. PM obtained from CMAQ modeling data 2.5 was estimated using a meteorological research and forecasting model consisting of three overlapping meteorological data sources at 3, 9, and 27 km for a specific period. PM during pregnancy 2.5 The exposure level was determined based on the residential address (city, county, district). For each address, daily PM 2.5 Concentrations were matched to each individual according to the due date. Groups were stratified by birth weight and height, and Student's t-tests were performed. Low birth weight was defined as birth weight <2,500 g, and low birth height (LBH) was defined as birth height <46.3 cm for boys and <45.6 cm for girls.

[0059] (2) Study design of Cohort II

[0060] For the multicenter prospective cohort study (APPO) on air pollution in pregnant women, >1,200 participants were recruited from seven university hospitals nationwide from January 2021 to December 2023. Each hospital was located in the metropolitan area, an industrial complex area, or a mountainous area, and participants were pregnant women without underlying diseases before 28 weeks of gestation. The study included 333 women who had given birth. Data on basic demographic and health-related characteristics, including age, BMI, socioeconomic status, and obstetric history, were collected. Urine samples were also collected during the second trimester of pregnancy, and pregnancy outcomes were assessed postpartum.

[0061] This study was approved by the Ethics Committee of Ewha Womans University Mokdong Hospital (EUMC 2021-04-032), Yonsei University Severance Hospital (4-2021-0414), Kangwon National University Hospital (KNUH-B-2021-04-012-008), Keimyung University Dongsan Hospital (2021-04-073), Korea University Guro Hospital (2021GR0233), Ewha Womans University Seoul Hospital (2021-04-022), and Ulsan University Hospital (2022-04-020). All participants provided written informed consent.

[0062] (3) Fine dust exposure assessment

[0063] Indoor PM 2.5 Concentrations were measured by placing a fine dust meter in the living room of the pregnant woman's home at her breathing height. The AirGuard K (Kweather, Co., Korea) device was used for measurements using the sensor method. Indoor PM 2.5 was measured at 1-minute intervals. Measured indoor PM 2.5 Data were stored on an indoor air quality monitoring platform (IAQ Station) using long-term evolution. Measurements were conducted for at least one week each trimester, and the measured concentration values ​​were recorded in real time.

[0064] Outdoor PM2.5 Concentrations were collected from a network of urban air quality monitoring stations located near the study participants' residential addresses. The urban air quality monitoring station data used in this study were obtained from the Air Korea database (https: / / www.airkorea.or.kr / web) of the Ministry of Environment of Korea.

[0065] (4) Collection of urine samples

[0066] A 15 ml urine sample was collected. Blood samples were collected during regular follow-up and stored in frozen tubes. The samples were transported to the institution (Seegene Medical Foundation, Seoul, Korea) on the same day and refrigerated at -80°C to prevent deterioration.

[0067] (5) Statistical analysis

[0068] Participants were assigned to PM 2.5 exposure levels <10 ㎍ / m2, which is the World Health Organization (WHO) annual limit standard concentration (2005 Air Quality Guidelines). 3 (low PM 2.5 Concentration exposure group) and ≥10 ㎍ / m 3 (High PM 2.5 Divided into groups (concentration exposure group).

[0069] Categorical variables were analyzed using the chi-square test and Fisher's exact test. Continuous variables were compared using the Mann-Whitney U test or Student's t-test. Statistical significance was defined as P < 0.05. All statistical analyses were performed using the Statistical Package for the Social Sciences (version 20.0) (Chicago, IL, USA).

[0070] B. Results

[0071] (1) Fine dust (PM) in Cohort 1 study group 2.5 ) Analysis of the association between exposure and pregnancy complications

[0072] Fine dust (PM) 2.5) As a result of examining the association between exposure and pregnancy complications, as shown in Table 1 below, 1,569 of the 1,880 newborns were normal birth weight (NBW) and 311 were low birth weight (LBW). The two groups showed significant differences in gestational age at birth (GAB), birth weight, length, and APGAR score, and preterm birth (PTB) as a pregnancy complication (P<0.01), but there were no significant differences in maternal age, maternal pre-pregnancy BMI, and newborn sex.

[0073] In addition, as shown in Table 2 below, the concentration of fine dust exposed to pregnant women who gave birth to low birth weight babies during the second trimester was 27.21 μg / m 3 26.23 μg / m in the group of pregnant women who gave birth to normal-weight infants 3 It was found to be significantly higher.

[0074]

[0075] Characteristics of Cohort I Study GroupCharacteristicsNBW(n=1569)LBW(n=311)p-valueMaternal age (years)33.204.1632.794.470.12Pre-BMI (kg / m) 2 )21.463.5921.523.650.92GAB Co., Ltd. 39.021.3533.303.49<0.01*Newborn sex (male) 79182.14%17217.86%0.12Newborn sex (female) 78084.78%14015.22%Birth weight (g) 3266.44394.831824.04497.55<0.01*Birth height (cm) 49.761.8842.084.06<0.01*APGAR 1 minute 9.301.126.762.54<0.01*APGAR 5 minutes 9.880.558.272.24<0.01*PTB8124.40%25175.60%<0.01*

[0076] * Categorical variables were expressed as frequencies (percentages) and analyzed using the chi-square test. Continuous variables were expressed as mean ± standard deviation and compared using the t-test (right columns for NBW and LBW). * BMI, body mass index; GAB, gestational age at birth; APGAR, appearance, pulse, grimace, activity, and respiration; PTB, preterm birth. * P < 0.05 was considered statistically significant.

[0077]

[0078] Fine dust (PM) by pregnancy period in normal-weight and low-birth-weight infants 2.5 ) Exposure amount (μg / m) 3 ) Comparison of exposure periods NBW (n = 1567) LBW (n = 313) p-value Total pregnancy period 27.17 ± 4.3 0 4.67 ± 27.4 0 0.43 Early pregnancy (1 st trimester)28.75 ± 7.6328.04 ± 7.700.15Second trimester (2) nd trimester)26.23 ± 6.7827.21 ± 6.530.02*Late pregnancy (3) rd trimester)26.40 ± 6.4327.04 ± 8.560.23

[0079] * Continuous variables are expressed as mean ± standard deviation and compared using t-test. * P < 0.05 is considered statistically significant.

[0080]

[0081] Meanwhile, as shown in Table 3 below, when newborns were divided into the full-term group (>37 weeks) and the PTB group, and when divided into the premature group (PTB, <37 weeks), the PM for low birth weight (LBW) 2.5 The exposure concentration is 27.29 μg / m 3 The concentration in normal birth weight (NBW) infants (25.89 μg / m) 3 ) was significantly higher than that of the preterm birth (PTB) group (P=0.02). In addition, in the preterm birth (PTB) group, PM 2.5The preterm normal birth weight (PNBW) and preterm low birth weight (PLBW) groups according to exposure concentration showed significant differences between the early and late periods, respectively (P = 0.05, P = 0.04). Meanwhile, as shown in Table 4 below, in the model adjusted for maternal age, parity, maternal prepregnancy body mass index, preeclampsia, and gestational age, PM 2.5 Pregnant women exposed to PM 2.5 The risk of low birth weight (LBW) was significantly higher in pregnant women exposed to ethanol than in pregnant women not exposed to ethanol, with an adjusted odds ratio (OR) of 1.06 (95% confidence interval [CI]: 1.01–1.10).

[0082]

[0083] Fine dust (PM) by pregnancy period in premature infants, both normal-birth-weight (NBW) and low-birth-weight (LBW) infants 2.5 ) Exposure amount (μg / m) 3 ) Comparison of exposure periods NBW (n = 84) LBW (n = 260) p-value Total pregnancy period 25.89 ± 4.15 27.29 ± 4.7 80.02 Early pregnancy (1 st trimester)25.81 ± 6.6327.58 ± 7.570.05Second trimester (2) nd trimester)25.57 ± 6.2627.25 ± 6.580.04Late pregnancy (3) rd trimester)26.69 ± 6.1527.23 ± 8.980.55

[0084] * Continuous variables are expressed as mean ± standard deviation and compared using t-test. * P < 0.05 is considered statistically significant.

[0085]

[0086] Fine dust (PM) by pregnancy period 2.5 ) Exposure amount (μg / m) 3 ) and low birth weight (LBW): A logistic regression analysis. Risk of LBW by PM 2.5 Exposure (1 μg / m3 ) Risk of low birth weight according to OR95%, CIp-value Total pregnancy period 1.061.01, 1.100.02* Early pregnancy (1 st trimester)1.021.00, 1.050.08 Second trimester (2) nd trimester)1.031.00, 1.060.04*Later trimester (3) rd trimester)1.000.98, 1.030.80

[0087] *OR, odds ratio; Cl, ​​confidence interval. *P<0.05 is considered statistically significant.

[0088]

[0089] (2) Fine dust (PM) in the cohort Ⅱ study group 2.5 ) Association between exposure concentration and pregnancy complications

[0090] As shown in Table 5, the average birth height was PM 2.5 In the high concentration exposure group, it was 48.9 cm, PM 2.5 It was significantly lower than the low-concentration exposure group (49.5 cm) (P=0.04). In addition, PM 2.5 In the high-concentration exposure group, preterm birth (PTB) significantly increased from 4.2% to 13.2%, and small-for-gestational-age (SGA) infants significantly increased from 0.6% to 5.1% (P<0.01, P=0.01).

[0091] Also, as shown in Figure 1, high concentration of PM 2.5 The longer the exposure, the higher the risk of admission to the neonatal intensive care unit (NICU) due to pregnancy complications such as premature birth, gestational diabetes, and low birth weight.

[0092]

[0093] Fine dust (PM) 2.5 ) Association between exposure and pregnancy complications 2.5 Low-concentration exposure group (n=191) PM 2.5High-concentration exposure group (n=115) p-value GAB (week) 38.22± 1.59 37.96± 1.95 0.22 Delivery mode 0.86 ND 6 136.5% 5 137.5% CS 10 66 3.5% 8 5 6 2.5% Birth weight (g) 3 15 0.7± 391.63 112.0± 5 22.5 0.50 Birth height (cm) 49.5± 2.24 8.9± 2.8 0.04 * APGAR 1 minute 8.45± 1.22 8.36 0.61 APGAR 5 minutes 9.43± 0.84 9.21± 1.370.13LBW45.1%46.9%0.47NBW52.6%87.0%0.07PTB84.2%1513.2%<0.01*SGA10.6%75.1%0.01*NICU admission2012.0%2316.9%0.32

[0094] * Categorical variables were expressed as frequencies (percentages) and analyzed using chi-square and Fisher's exact tests. Continuous variables were expressed as mean ± standard deviation (SD) or median (interquartile range) and compared using the t-test or Mann-Whitney U test. * GAB, gestational age at birth; ND, normal birth; CS, cesarean section; APGAR, appearance, pulse, frown, activity, and respiration; LBW, low birth weight; LBH, short birth height; PTB, preterm birth; SGA, small for gestational age; NICU, neonatal intensive care unit. * P < 0.05 was considered statistically significant.

[0095]

[0096] Example 2. Screening of biomarkers for predicting pregnancy complications due to exposure to fine dust.

[0097] A. Experimental subjects, materials, and experimental methods

[0098] (1) Sample pretreatment method

[0099] The experimental subjects were the same pregnant women as the Cohort II study subjects.

[0100] (2) Sample pretreatment method

[0101] A 50 μl urine sample was placed in a microtube, and 100 μl of a urease solution dissolved in water at a concentration of 1 mg / ml was added. To decompose urea, which is saturated and acts as an interference substance in the analysis, ultrasonication was performed for 1 h at room temperature using a water bath ultrasonicator, and after ultrasonication, 150 μl of methanol was added.

[0102] Afterwards, liquid liquid extraction (LLE) was performed using chloroform. Specifically, 150 μL of chloroform was added and vortexed for about 1 minute to ensure sufficient mixing of the solution. Afterwards, centrifugation was performed at 13,000 × g for 5 minutes at room temperature to separate the layers. Through centrifugation, the lower layer was divided into a chloroform layer (nonpolar metabolite layer), the middle layer was a protein layer, and the upper layer was a water and methanol solution layer (polar metabolite layer). Then, only the lower layer, the chloroform layer, was fractionated using a micropipette.

[0103] Afterwards, 150 μl of chloroform was added again, and the above process was repeated once. The chloroform layer was completely separated, and only the water-methanol solution layer was separated from the remaining protein layer and water-methanol solution layer. The separated water-methanol solution layer was filtered using a PTFE syringe filter with a particle size of 0.45 μm. The sample was then evaporated to dryness using a nitrogen concentrator.

[0104] Afterwards, derivatization was performed using methoxyamine and N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane. 50 μl of a 20 mg / ml methoxyamine solution dissolved in pyridine was added to the evaporated-dried sample, and incubated at 37°C for 90 minutes. Afterwards, 50 μl of a N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane solution was added, and pretreatment was performed by incubating at 70°C for 1 hour.

[0105] (3) Device analysis

[0106] Gas chromatography was performed on a Shimadzu QP2010 GC-MS system from Shimadzu Corporation, using a DB-5MS (30 m x 0.25 mm, 0.25 μm) chromatography column. 1 μl of sample was injected, and the injection temperature was set to 270°C. The injection method was splitless, the column flow rate was 1 ml / min, and high-purity helium was used as the mobile phase gas. The oven was initially maintained at 70°C for 2 minutes, then increased to 100°C at a heating rate of 4°C / min and maintained for 3 minutes, then increased to 160°C at a heating rate of 3°C / min and maintained for 1 minute, then increased to 200°C at a heating rate of 4°C / min and maintained for 2 minutes, and then increased to 300°C at a heating rate of 8°C / min and maintained for 10 minutes, for a total of 68 minutes of analysis. The temperature of the gas chromatography and mass spectrometer connection was 300°C, and the temperature of the ion source was 250°C. Analysis was performed in scan mode in the m / z range of 40–600. Data analysis was performed using Shimadzu GCMS Real Time Analysis and Shimadzu GCMS Postrun Analysis, and the library search of mass spectrometry spectra was performed using the NIST Mass Spectral Library (NIST 08).

[0107] (4) Metabolite identification

[0108] Metabolites were identified by comparing the retention index and mass spectra of the chromatograms of the standard and urine samples after standard analysis.

[0109] (5) Statistical analysis

[0110] Raw data were converted to a format suitable for statistical analysis using MetAlign software. The converted data were then statistically processed using MetaboAnalyst 5.0.

[0111] B. Experimental results

[0112] (1) Multivariate statistical analysis

[0113] (a) Orthogonal partial least squares discriminant analysis (OPLS-DA)

[0114] As shown in Fig. 2, PM 2.5 High-concentration exposure group (hereinafter referred to as high-concentration group) and PM 2.5 Metabolites that showed significant differences between the low-concentration exposure groups (hereafter, the low-concentration group) were listed from the top in order of greatest impact. As a result, ribose, arabinose, and xylose were all confirmed to have high significance with VIP scores of 1.0 or higher.

[0115] In addition, as shown in Fig. 3, the fold change plot of the sugar metabolites was used to represent the logarithmic difference in metabolite ratio between the low-concentration group and the high-concentration group. When the ratio difference of more than 2-fold was determined to be a significant metabolite, no disaccharides or hexoses were identified as significant metabolites, but all three identified pentose metabolites (Ribose, Arabinose, and Xylose) were identified as significant metabolites. Specifically, disaccharide and hexose metabolites did not necessarily increase in the high-concentration group, but some decreased, but in the case of pentose, Arabinose was confirmed to increase in the high-concentration group compared to the low-concentration group by about 2.6 times, Ribose by about 2.7 times, and Xylose by about 14.6 times.

[0116] All three detected pentose sugars (Ribose, Arabinose, and Xylose) were identified as significant metabolites, and judging from the fact that they showed different change patterns from other metabolites, it was determined that exposure to fine dust had a major impact on the metabolism of pentose sugars.

[0117] (I) Stud'nt's T-test

[0118] As shown in Table 6, all three types of pentose sugars (Ribose, Arabinose, and Xylose) were found to have significant differences between the high-concentration and low-concentration groups at a 95% confidence level (P value < 0.05).

[0119] Stud'nt's T-test resultsMetabolitep-valueRibose8.99E-07Arabinose6.52E-05Xylose9.80E-03

[0120] *OR, odds ratio; Cl, ​​confidence interval. *P<0.05 is considered statistically significant.

[0121]

[0122] (All) ROC curve

[0123] The ROC curve is a graph that shows the performance of a classification model. A wider AUC (Area Under the Curve) indicates a better model's ability to distinguish groups. As shown in Figure 4, when only metabolites with an AUC greater than 0.7 were identified as significant metabolites, the three pentose metabolites, namely ribose, arabinose, and xylose, had AUC values ​​of 0.95, 0.876, and 0.89, respectively, indicating that they were all classified as significant metabolites.

[0124]

[0125] Example 3. Revalidation of Prediction of Pregnancy Complications Caused by Fine Dust Exposure Using Selected Biomarkers

[0126] To verify whether the biomarker selected in Example 2 above is suitable as a biomarker for predicting pregnancy complications due to actual fine dust exposure, an experiment was conducted using the urine samples used in Example 2. As a control group, urine samples from mothers randomly selected from the group with the lowest individual measured fine dust concentration during pregnancy were used.

[0127] Specifically, samples with significantly increased levels of ribose or arabinose detected in urine samples compared to the control group were selected, and the accuracy (P-value) was determined by confirming the pregnancy information of the pregnant women in the samples.

[0128] Results from the experiment confirmed that both ribose and arabinose were able to accurately predict pregnancy complications (preterm birth, preeclampsia, gestational diabetes, NICU admission due to pregnancy complications such as low birth weight, and birth defects).

[0129] PM with ribose as a biomarker 2.5 Prediction of pregnancy complications by exposure level LowMedHighP-valuePTB0013.30%0.044*Reeclampsia006.70%0.157GDM06.70%20.00%0.049*NICU03.30%13.30%0.097Anomaly006.70%0.157

[0130]

[0131] PM with arabinose as a biomarker 2.5 Prediction of pregnancy complications by exposure level LowMedHighP-valuePTB0013.30%0.044*Preeclampsia006.70%0.157GDM6.70%6.70%13.30%0.512NICU03.30%13.30%0.097

[0132] * PTB, preterm birth; Preeclampsia, preeclampsia; GDM, gestational diabetes mellitus; NICU, admission to the neonatal intensive care unit due to pregnancy complications such as low birth weight; Anomaly, birth defect. *P<0.05 is considered statistically significant.

Claims

1. (a) A method for providing information for distinguishing pregnant women exposed to fine dust, comprising the step of quantifying the level of at least one metabolite selected from the group consisting of arabinose, ribose, and xylose from a sample of a subject suspected of being exposed to fine dust.

2. A method for providing information, further comprising: a step of determining that exposure to fine dust has occurred when, in the first paragraph, (b) the level of the metabolite is increased compared to at least one selected from the group consisting of arabinose, ribose, and xylose of the corresponding normal control group as a result of quantifying the level of the metabolite.

3. A method for providing information, further comprising: (b) a step of predicting that there is a risk of developing pregnancy-related complications due to exposure to fine dust when the level of the metabolite is increased as a result of quantifying the level of the metabolite compared to at least one selected from the group consisting of arabinose, ribose, and xylose of the corresponding normal control group.

4. A method for providing information in claim 2 or 3, wherein the level of the metabolite is a quantitative measurement of the quantity, level, distribution, distribution ratio, or concentration of at least one metabolite selected from the group consisting of arabinose, ribose, and xylose in a biological sample.

5. A method for providing information in paragraph 1, wherein the sample of the subject is a biological sample separated from the subject.

6. In the fifth paragraph, the biological sample is any one selected from blood, plasma, platelets, serum, ascites fluid, bone marrow fluid, lymph, saliva, tears, mucous membrane fluid, amniotic fluid, feces, vaginal fluid, and urine separated from the subject.

7. A method for providing information in the second paragraph, wherein the normal control group is a healthy human or mammal not exposed to fine dust.

8. In the third paragraph, the normal control group is a soldier with a low estimated concentration of fine dust exposure, information provision method.

9. A method for providing information in paragraph 3, wherein the pregnancy-related complication is any one selected from among low birth weight, high risk of miscarriage and premature birth, intrauterine fetal death, congenital malformation, increased incidence of neonatal diseases, increased perinatal mortality in newborns, premature birth, and gestational diabetes.

10. A method for providing information, wherein the step of quantifying the metabolite in the first paragraph is performed by at least one selected from the group consisting of a gas or liquid chromatography device, a high-performance liquid chromatography (HPLC) device, a thin layer chromatography (TLC), an electrochemical analysis device, a refractive index spectroscopy device, a fluorescence analysis device, a radiochemical analysis device, a light scattering analysis device, a nuclear magnetic resonance spectroscopy, an ultraviolet spectroscopy, an infrared spectroscopy, an enzyme-linked immunosorbent assay (ELISA), and a mass spectrometer.

11. A composition for classifying exposure to fine dust in pregnant women, comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

12. A composition for predicting the onset of pregnancy-related complications due to exposure to fine dust in pregnant women, comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

13. A kit for classifying exposure to fine dust in pregnant women, comprising a composition comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

14. A kit for predicting the onset of pregnancy-related complications in a pregnant woman, comprising a composition comprising a preparation for quantifying at least one metabolite selected from the group consisting of arabinose, ribose, and xylose.

Citation Information

Patent Citations

  • Biomarker compositions and methods

    KR1020140067001A